Phaseline

Companies › ASC Therapeutics

ASC Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASC618
AAV vector encoding B-domain deleted codon-optimized human factor VIII
F8Phase 1Hemophilia ADec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04676048ASC618Phase 1Hemophilia AHematologyDec 2026

Targets

F8 (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech Octapharma Bioverativ, a Sanofi company Biocad Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.